ClinicalTrials.gg
CompletedNCT00569192Updated Jan 9, 2014Results posted

A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children

A Phase 3 interventional study of 0.135mg MAP0010 and 0.25mg MAP0010 in Asthma, sponsored by Allergan. Completed. Open to participants aged 12 Months to 8 Years. Per ClinicalTrials.gov, last updated 2014-01-09.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
12 Months to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
33rd of 108
360 · median 124
Started
2007
with 11 others
Phase 3
51 of 110
3 open now
Registered
33rd of 110
by date
Lead sponsor
5 of 110
Allergan

Among the 110 studies testing budesonide in Asthma, this one is the 33rd largest by enrollment of the 108 interventional ones that give a count, is one of 12 that started in 2007, is one of 51 in phase 3, and was the 33rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Months to 8 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to examine the safety and efficacy of two doses of MAP0010 versus placebo in asthmatic infants and children, 12 months to 8 years of age, over a 12-week treatment period.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthmatic children
04

Who can participate

Ages eligible
12 Months to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female asthmatic children with mild to moderate persistent asthma.
  • 12 months to 8 years of age.
  • For children age 4 to 8 years: Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH (EPR-3) criteria.
  • For infants age 12 to \<48 months old: 2 or more wheezing episodes in past 12 months which lasted > 1 day and affected sleep.
  • AND with at least one major or two minor risk factors.

Exclusion criteria

Exclusion Criteria:

  • Any other significant childhood illness/abnormality or chronic lung disease
  • Any history of upper or lower respiratory tract infection, within 2 weeks of screening.
  • Any history of acute or severe asthma attack requiring ICU admission or ventilatory support.
  • Use of any , including inhaled, parental, intranasal, or topical corticosteroid within 2 weeks of screening.
  • Any use of oral corticosteroids within 30 days of screening or prolonged use (>10 consecutive days) of oral corticosteroids, within 12 weeks of screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    0.25mg MAP0010

    0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks

    Drug: 0.25mg MAP0010

  • Placebo comparator
    Placebo

    Placebo delivered by nebulization twice daily for 12 weeks

    Drug: Placebo

  • Experimental
    0.135mg MAP0010

    0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks

    Drug: 0.135mg MAP0010

Interventions

  • 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks

  • 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks

  • DrugPlacebo

    Placebo delivered by nebulization twice daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Daytime Composite Symptom Score

    The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 7 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

    Time frame: baseline, week 12

  2. Change From Baseline in Nighttime Composite Symptom Score

    The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 7 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

    Time frame: baseline, week 12

Secondary outcomes

  1. Change From Baseline in FEV1% Predicted

    The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer and the largest volume from the 3 maneuvers was selected. An increase indicates an improvement (a greater volume of air expired).

    Time frame: baseline, week 12

  2. Change From Baseline in PEF

    The peak expiratory flow (PEF) is the highest air flow achieved from a maximum forced expiratory maneuver measured in liters of air per minute (L/min). Subjects had to perform at least 3 acceptable maneuvers into a PEF meter. An increase indicates an improvement (a greater volume of air expired).

    Time frame: baseline, week 12

  3. Change From Baseline in Daytime Individual Symptom Scores

    The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Individual Daytime symptom score is defined as an average of the last 5 days' individual symptom scores within the last 7 days immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

    Time frame: baseline, week 12

  4. Change From Baseline in Nighttime Individual Symptom Scores

    The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Individual nighttime symptom score is defined as an average of the last 5 nights' individual symptom scores within the last 7 nights immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

    Time frame: baseline, week 12

07

Results

Posted Oct 23, 2013

Participant flow

Participant flow — Overall Study
MilestonePlacebo0.135 mg MAP00100.25 mg MAP0010
Started111125124
Completed8810599
Not completed232025

Outcome measures

PrimaryChange From Baseline in Daytime Composite Symptom Score

The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 7 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

Time frame:
baseline, week 12
Reported as:
Mean · units on a scale
Change From Baseline in Daytime Composite Symptom Score
units on a scalePlacebo0.135 mg MAP00100.25 mg MAP0010
Baseline2.73 ± 1.4062.96 ± 1.3292.87 ± 1.383
Change from Baseline at week 12-1.38 ± 1.722-1.77 ± 1.618-1.56 ± 1.591
SecondaryChange From Baseline in FEV1% Predicted

The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer and the largest volume from the 3 maneuvers was selected. An increase indicates an improvement (a greater volume of air expired).

Time frame:
baseline, week 12
Reported as:
Mean · percentage of predicted FEV1
Change From Baseline in FEV1% Predicted
percentage of predicted FEV1Placebo0.135 mg MAP00100.25 mg MAP0010
Baseline96.96 ± 18.64691.20 ± 17.71393.00 ± 17.305
Change from Baseline at Week 121.51 ± 13.0684.14 ± 12.8450.36 ± 16.657
PrimaryChange From Baseline in Nighttime Composite Symptom Score

The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 7 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

Time frame:
baseline, week 12
Reported as:
Mean · units on a scale
Change From Baseline in Nighttime Composite Symptom Score
units on a scalePlacebo0.135 mg MAP00100.25 mg MAP0010
Baseline2.71 ± 1.3932.97 ± 1.4662.82 ± 1.349
Change from Baseline at week 12-1.47 ± 1.572-1.82 ± 1.907-1.59 ± 1.516
SecondaryChange From Baseline in PEF

The peak expiratory flow (PEF) is the highest air flow achieved from a maximum forced expiratory maneuver measured in liters of air per minute (L/min). Subjects had to perform at least 3 acceptable maneuvers into a PEF meter. An increase indicates an improvement (a greater volume of air expired).

Time frame:
baseline, week 12
Reported as:
Mean · L/min
Change From Baseline in PEF
L/minPlacebo0.135 mg MAP00100.25 mg MAP0010
Baseline170.94 ± 49.343163.39 ± 52.881165.34 ± 49.133
Change from Baseline at Week 120.71 ± 44.54420.10 ± 45.44415.02 ± 45.306
SecondaryChange From Baseline in Daytime Individual Symptom Scores

The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Individual Daytime symptom score is defined as an average of the last 5 days' individual symptom scores within the last 7 days immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

Time frame:
baseline, week 12
Reported as:
Mean · units on a scale
Change From Baseline in Daytime Individual Symptom Scores
units on a scalePlacebo0.135 mg MAP00100.25 mg MAP0010
Cough: Baseline1.16 ± 0.5441.21 ± 0.4901.18 ± 0.582
Cough: Change from Baseline at week 12-0.55 ± 0.734-0.68 ± 0.705-0.58 ± 0.664
Wheeze: Baseline0.84 ± 0.5910.91 ± 0.5460.88 ± 0.550
Wheeze: Change from Baseline at week 12-0.45 ± 0.615-0.58 ± 0.563-0.49 ± 0.589
Shortness of Breath: Baseline0.73 ± 0.5570.84 ± 0.6120.81 ± 0.602
Shortness of Breath: Change from Baseline at Wk 12-0.37 ± 0.635-0.51 ± 0.632-0.49 ± 0.626
SecondaryChange From Baseline in Nighttime Individual Symptom Scores

The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Individual nighttime symptom score is defined as an average of the last 5 nights' individual symptom scores within the last 7 nights immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

Time frame:
baseline, week 12
Reported as:
Mean · units on a scale
Change From Baseline in Nighttime Individual Symptom Scores
units on a scalePlacebo0.135 mg MAP00100.25 mg MAP0010
Cough: Baseline1.16 ± 0.5281.20 ± 0.4951.17 ± 0.565
Cough: Change from Baseline at week 12-0.59 ± 0.663-0.69 ± 0.720-0.61 ± 0.638
Wheeze: Baseline0.83 ± 0.5630.94 ± 0.5920.90 ± 0.548
Wheeze: Change from Baseline at week 12-0.48 ± 0.594-0.57 ± 0.704-0.51 ± 0.603
Shortness of Breath: Baseline0.72 ± 0.5430.83 ± 0.6220.75 ± 0.569
Shortness of Breath: Change from Baseline at Wk 12-0.39 ± 0.549-0.56 ± 0.690-0.47 ± 0.566

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/110 (0.9%)33/110 (30%)
0.135 mg MAP0010—2/123 (1.6%)31/123 (25.2%)
0.25 mg MAP0010—0/123 (0%)42/123 (34.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo0.135 mg MAP00100.25 mg MAP0010
AsthmaRespiratory, thoracic and mediastinal disorders1/1101/1230/123
Pneumonia NecrotisingInfections and infestations0/1101/1230/123
Most frequent other events
Most frequent other events
EventPlacebo0.135 mg MAP00100.25 mg MAP0010
Upper Respiratory Tract InfectionsInfections and infestations13/11017/12319/123
AsthmaRespiratory, thoracic and mediastinal disorders11/1109/12315/123
PyrexiaGeneral disorders9/1105/1238/123
NasopharyngitisInfections and infestations5/1102/1237/123

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo0.135 mg MAP00100.25 mg MAP0010Total
Mean4.5 ± 2.174.4 ± 2.334.2 ± 2.274.4 ± 2.26
Age, Continuous
Age, Continuous(years)Placebo0.135 mg MAP00100.25 mg MAP0010Total
Median4.0 (1 to 8)4.0 (1 to 8)4.0 (1 to 8)4.0 (1 to 8)
Sex: Female, Male
Sex: Female, Male(Participants)Placebo0.135 mg MAP00100.25 mg MAP0010Total
Female455049144
Male667575216
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Sep 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2007
First posted
Dec 7, 2007
Start
Dec 2007
Primary completionActual
Sep 2008
CompletionActual
Jan 2009
Results first posted
Oct 23, 2013
Last update
Jan 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00569192
Lead sponsor
Allergan
Collaborators
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Responsible party
Sponsor
First posted
Dec 7, 2007
Start date
Dec 2007
Primary completion
Sep 2008
Completion
Jan 2009
Results posted
Oct 23, 2013
Last update
Jan 9, 2014

Study contacts

Medical Director
study director · MAP Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion